# Interesting drugs in development
**URL:** https://forum.fudiabetes.org/t/interesting-drugs-in-development/12427
**Category:** T1 Research
**Created:** [February 22, 2022, 11:25pm UTC](https://forum.fudiabetes.org/t/interesting-drugs-in-development/12427 "2022-02-22T23:25:13Z")
**Posts on this page:** 10
**Page:** 1
### Author:  [@TiaG](https://forum.fudiabetes.org/u/TiaG)
#### Post date: [February 22, 2022, 11:25pm UTC](https://forum.fudiabetes.org/t/interesting-drugs-in-development/12427/1 "2022-02-22T23:25:13Z")
These are still in early development, but both sound like promising approaches to reduce hypoglycemia:
> **[TTP399 - VTV Therapeutics](https://vtvtherapeutics.com/pipeline/ttp399/)**
>
> TTP399 Type 1 Diabetes and Hypoglycemia Type 1 Diabetes (T1D) is an autoimmune disease with no cure affecting over 1.6 million people in the United States. Adult-onset T1D has become more common than childhood-onset with more than half of all new...
Even earlier:
> **[Effect of ZT-01 on Glucagon During Hypoglycemia in Type 1 Diabetes Mellitus -...](https://www.clinicaltrials.gov/ct2/show/NCT05007977)**
>
> Effect of ZT-01 on Glucagon During Hypoglycemia in Type 1 Diabetes Mellitus - Full Text View.
I know many folks on here who are not worried about hypos, but for us, hypos are a barrier that prevent us from targeting normoglycemic blood sugars.
---
### Author:  [@MM2](https://forum.fudiabetes.org/u/MM2)
#### Post date: [February 23, 2022, 6:44pm UTC](https://forum.fudiabetes.org/t/interesting-drugs-in-development/12427/2 "2022-02-23T18:44:22Z")
> [@TiaG](#):
>
> hypos are a barrier that prevent us from targeting normoglycemic blood sugars.
Agree!!
Also found this comment interesting.
“Adult-onset T1D has become more common than childhood-onset with more than half of all new cases diagnosed in adult patients.”
---
### Author:  [@jim26](https://forum.fudiabetes.org/u/jim26)
#### Post date: [February 23, 2022, 6:57pm UTC](https://forum.fudiabetes.org/t/interesting-drugs-in-development/12427/3 "2022-02-23T18:57:23Z")
> [@TiaG](#):
>
> I know many folks on here who are not worried about hypos, but for us, hypos are a barrier that prevent us from targeting normoglycemic blood sugars.
Very cool and we should all be concerned about hypos especially at night.
---
### Author:  [@Boerenkool](https://forum.fudiabetes.org/u/Boerenkool)
#### Post date: [February 23, 2022, 7:00pm UTC](https://forum.fudiabetes.org/t/interesting-drugs-in-development/12427/4 "2022-02-23T19:00:28Z")
Interesting stuff! I’d love something to help prevent hypoglycemia. Too bad the information about the mechanisms of action is so limited.
---
### Author:  [@Chris](https://forum.fudiabetes.org/u/Chris)
#### Post date: [March 2, 2022, 10:37pm UTC](https://forum.fudiabetes.org/t/interesting-drugs-in-development/12427/5 "2022-03-02T22:37:56Z")
I find it quite hopeful that two drugs are aimed at Type 1’s rather than the larger Type 2 market. A good sign.
---
### Author:  [@TomH](https://forum.fudiabetes.org/u/TomH)
#### Post date: [March 6, 2022, 2:50pm UTC](https://forum.fudiabetes.org/t/interesting-drugs-in-development/12427/6 "2022-03-06T14:50:02Z")
@MM2 I can’t help but wonder if the increase in adult T1D is actually an increase or if awareness of the potential, testing, and finding adults with T1D has just occurred and the numbers have been there all along. A I’m a gray vs black&white kind of guy, its’ probably a bit of both…
Using myself as an example: I went to the USAF Academy as a young pup, but almost got eliminated based on a physical. I had to take a GTT three times because of the findings (I don’t know the specifics, I just drank the coke bottle of glucose and played the vampire’s victim for blood letting!). I also got warned by one of the admin NCOs that I was borderline underweight (at the time USAF took underweight more seriously than overweight). Looking back on it some 40 years later, I suspect my LADA or other diabetes name had already had sufficient effect to make the GTTs suspect, but not sufficiently defining. The weight loss issue was what drove the final testing resulting in my D diagnosis, though it was for T2 at first, finally T1 when a GAD test was done.
---
### Author:  [@TomH](https://forum.fudiabetes.org/u/TomH)
#### Post date: [March 6, 2022, 2:51pm UTC](https://forum.fudiabetes.org/t/interesting-drugs-in-development/12427/7 "2022-03-06T14:51:25Z")
Can someone define a “mechanistic” study for me? I’ll look it up as well…
---
### Author:  [@TomH](https://forum.fudiabetes.org/u/TomH)
#### Post date: [March 6, 2022, 2:53pm UTC](https://forum.fudiabetes.org/t/interesting-drugs-in-development/12427/8 "2022-03-06T14:53:22Z")
Found this re “mechanistic”: NIH defines mechanistic studies as **designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention**. Not all mechanistic studies are clinical trials, but many are.
---
### Author:  [@MM2](https://forum.fudiabetes.org/u/MM2)
#### Post date: [March 6, 2022, 4:29pm UTC](https://forum.fudiabetes.org/t/interesting-drugs-in-development/12427/9 "2022-03-06T16:29:09Z")
> [@TomH](#):
>
> if awareness of the potential, testing, and finding adults with T1D has just occurred
I agree this is the case.
With “classic” juvenile diabetes, the symptoms come on more quickly. Parent or individual is likely to notice weight loss, tiredness, and do something about it. My mom noticed this when i was 5, went to doc, and sent directly to hospital (55+ years ago).
---
### Author:  [@bkh](https://forum.fudiabetes.org/u/bkh)
#### Post date: [March 6, 2022, 6:57pm UTC](https://forum.fudiabetes.org/t/interesting-drugs-in-development/12427/10 "2022-03-06T18:57:06Z")
> [@TomH](#):
>
> I can’t help but wonder if the increase in adult T1D is actually an increase or if awareness of the potential, testing, and finding adults with T1D has just occurred and the numbers have been there all along. A I’m a gray vs black&white kind of guy, its’ probably a bit of both…
Hmmm. Thinking out loud here, so this could be wrong: More widespread testing would reveal an underlying increase in prevalence _sooner_, but if there is no actual underlying increase in T1D, then increased testing would only add to the count by finding adults who otherwise would have died before diagnosis. I thought I vaguely recalled that LADA generally causes dramatic symptoms within a few years. If that’s true, then more widespread testing would’t find enough new cases to explain the rise. I don’t see an immediate flaw in this line of reasoning…